潍坊医学院学报
濰坊醫學院學報
유방의학원학보
Acta Academiae Medicinae Weifang
2015年
5期
330-332
,共3页
冠状动脉慢血流%尼可地尔%阿托伐他汀%hs-CRP%冠状动脉贮备功能
冠狀動脈慢血流%尼可地爾%阿託伐他汀%hs-CRP%冠狀動脈貯備功能
관상동맥만혈류%니가지이%아탁벌타정%hs-CRP%관상동맥저비공능
Coronary slow flow ( CSF)%Nicorandil%Atorvastatin%hs-CRP%CFR
目的 研究尼可地尔、阿托伐他汀、尼可地尔联合阿托伐他汀在冠状动脉慢血流( CSF )患者中的治疗作用,探讨单药物治疗和联合治疗的最佳方案. 方法 入选符合标准的病例92例,随机分为对照组23例、尼可地尔组22例、阿托伐他汀组22例和联合组25例,治疗3个月. 治疗前后测定包括超敏C反应蛋白( hs-CRP)、血常规及肝肾功能等指标;电话随访临床事件,腺苷负荷超声法记录冠脉分支血流频谱,计算注射腺苷后舒张期最大峰值血流速度( HCFV)与静息状态舒张期峰值血流速度( BCFV)的比值( CFR). 结果 尼可地尔、阿托伐他汀对CSF治疗有效,心绞痛症状明显缓解( A组缓解率68.18%,B组63.63%,联合组72. 00%,对照组21.74%);hs-CRP结果较治疗前和对照组明显降低,A组:(2.74±1.22),(3.72±1.78)mg/L;B组:(2.57±1.03), (3.86±1.95)mg/L;联合组:(2.69±1.40),(3.66±1.68)mg/L;对照组:(3.56±1.91),(3.77±1.99)mg/L,而各药物组之间比较差异无统计学意义;CFR 在药物组明显升高,尼可地尔组和联合组结果优于阿托伐他汀组,尼可地尔组和联合组比较差异无显著性(A组:2.81±0.49,2.10±0.48;B组:2.39±0.39,2.03±0.51;联合组:2.79±0.54,2.12±0.37;对照组:2.11±0.41,2.07±0. 47). 结论 CSF经过药物治疗均可显著缓解心绞痛症状,降低hs-CRP,改善冠脉贮备功能,但尼可地尔的治疗效果更优于阿托伐他汀,而两种药物联合较单用尼可地尔未体现出明显优势.
目的 研究尼可地爾、阿託伐他汀、尼可地爾聯閤阿託伐他汀在冠狀動脈慢血流( CSF )患者中的治療作用,探討單藥物治療和聯閤治療的最佳方案. 方法 入選符閤標準的病例92例,隨機分為對照組23例、尼可地爾組22例、阿託伐他汀組22例和聯閤組25例,治療3箇月. 治療前後測定包括超敏C反應蛋白( hs-CRP)、血常規及肝腎功能等指標;電話隨訪臨床事件,腺苷負荷超聲法記錄冠脈分支血流頻譜,計算註射腺苷後舒張期最大峰值血流速度( HCFV)與靜息狀態舒張期峰值血流速度( BCFV)的比值( CFR). 結果 尼可地爾、阿託伐他汀對CSF治療有效,心絞痛癥狀明顯緩解( A組緩解率68.18%,B組63.63%,聯閤組72. 00%,對照組21.74%);hs-CRP結果較治療前和對照組明顯降低,A組:(2.74±1.22),(3.72±1.78)mg/L;B組:(2.57±1.03), (3.86±1.95)mg/L;聯閤組:(2.69±1.40),(3.66±1.68)mg/L;對照組:(3.56±1.91),(3.77±1.99)mg/L,而各藥物組之間比較差異無統計學意義;CFR 在藥物組明顯升高,尼可地爾組和聯閤組結果優于阿託伐他汀組,尼可地爾組和聯閤組比較差異無顯著性(A組:2.81±0.49,2.10±0.48;B組:2.39±0.39,2.03±0.51;聯閤組:2.79±0.54,2.12±0.37;對照組:2.11±0.41,2.07±0. 47). 結論 CSF經過藥物治療均可顯著緩解心絞痛癥狀,降低hs-CRP,改善冠脈貯備功能,但尼可地爾的治療效果更優于阿託伐他汀,而兩種藥物聯閤較單用尼可地爾未體現齣明顯優勢.
목적 연구니가지이、아탁벌타정、니가지이연합아탁벌타정재관상동맥만혈류( CSF )환자중적치료작용,탐토단약물치료화연합치료적최가방안. 방법 입선부합표준적병례92례,수궤분위대조조23례、니가지이조22례、아탁벌타정조22례화연합조25례,치료3개월. 치료전후측정포괄초민C반응단백( hs-CRP)、혈상규급간신공능등지표;전화수방림상사건,선감부하초성법기록관맥분지혈류빈보,계산주사선감후서장기최대봉치혈류속도( HCFV)여정식상태서장기봉치혈류속도( BCFV)적비치( CFR). 결과 니가지이、아탁벌타정대CSF치료유효,심교통증상명현완해( A조완해솔68.18%,B조63.63%,연합조72. 00%,대조조21.74%);hs-CRP결과교치료전화대조조명현강저,A조:(2.74±1.22),(3.72±1.78)mg/L;B조:(2.57±1.03), (3.86±1.95)mg/L;연합조:(2.69±1.40),(3.66±1.68)mg/L;대조조:(3.56±1.91),(3.77±1.99)mg/L,이각약물조지간비교차이무통계학의의;CFR 재약물조명현승고,니가지이조화연합조결과우우아탁벌타정조,니가지이조화연합조비교차이무현저성(A조:2.81±0.49,2.10±0.48;B조:2.39±0.39,2.03±0.51;연합조:2.79±0.54,2.12±0.37;대조조:2.11±0.41,2.07±0. 47). 결론 CSF경과약물치료균가현저완해심교통증상,강저hs-CRP,개선관맥저비공능,단니가지이적치료효과경우우아탁벌타정,이량충약물연합교단용니가지이미체현출명현우세.
Objective To investigate the effects of atorvastatin and nicorandil ,which is more outstanding , Compared with single drug treatment , combined treatment is more outstanding or not .Methods A total of 92 patients with CSF but normal coronary angiography were included in this study , the patients were randomly assigned to control group of 23 cases,single drug group A(nicorandil) in 22 cases,single drug group B(atorvastatin) in 22 cases and com-bined treatment group (25 cases) .All the selected cases were given treatment for three months .Biochemical indexes were measured before and after treatment ,including the hs-CRP,routine blood,liver and kidney function and other biochemi-cal indicators;The clinical events of the patients were followed up by telephone ,using adenosine induced coronary artery to achieve maximum dilated state .Coronary reserve function was calculated by the ratio of maximal hyperemia and base-line peak diastolic coronary flow velocity ( HCFV and BCFV ) before and after treatment .Results After three months of treatment,Angina symptoms was relieved (groupA 68.18%,groupB 63.63%,joint group 72.00%,control group 21. 74%).The results of hs-CRP were significantly lower compared with the control group and before treatment (P<0.05), but there was no significant difference between the drug groups (P>0.05)(group A 2.74±1.22,3.72±1.78mg/L;group B 2.57±1.03,3.86±1.95mg/L;joint group 2.69±1.40,3.66±1.68mg/L;control group 3.56±1.91,3.77±1.99mg/L);CFR in the drug groups increased significantly , nicorandil group and combination group results better than atorvastatin group ,and there is no significant difference between the nicorandil group and combination grou ( group A 2.81±0.49,2.10±0.48;group B 2.39±0.39,2.03±0.51;joint group 2.79±0.54,2.12±0.37;control group 2.11±0.41,2.07±0.47).Conclusion Patients with CSF after nicorandil and atorvastatin therapy can relieve the symp-toms of angina pectoris significantly ,reduce hs-CRP,improve the CFR;Moreover,the treatment effect of nicorandil more better than atorvastatin ,and Combination therapy did not show obvious advantage .
